Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APYXNASDAQ:CTSONASDAQ:HYPRNYSE:VAPO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPYXApyx Medical$1.54-7.2%$1.16$0.76▼$1.95$58.20M1.1278,448 shs67,526 shsCTSOCytosorbents$0.85-0.5%$0.97$0.70▼$1.61$52.91M1.17146,059 shs52,325 shsHYPRHyperfine$0.54-5.7%$0.70$0.53▼$1.90$42.40M1.04403,793 shs596,652 shsVAPOVapotherm$2.17$2.16$0.70▼$3.44$13.58M-1.11N/A51,531 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPYXApyx Medical-7.23%+7.69%+71.13%+1.99%-3.75%CTSOCytosorbents-0.47%-6.11%-21.03%-26.52%-10.11%HYPRHyperfine-5.73%-12.31%-29.35%-47.11%-40.13%VAPOVapotherm0.00%0.00%0.00%0.00%+158.49%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPYXApyx Medical0.776 of 5 stars0.02.00.04.20.01.70.6CTSOCytosorbents2.1778 of 5 stars3.53.00.00.03.00.00.6HYPRHyperfine3.4884 of 5 stars3.35.00.00.02.92.51.3VAPOVapothermN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPYXApyx Medical 2.67Moderate BuyN/AN/ACTSOCytosorbents 3.00Buy$5.50550.89% UpsideHYPRHyperfine 2.67Moderate Buy$1.0694.57% UpsideVAPOVapotherm 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VAPO, APYX, CTSO, and HYPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/15/2025CTSOCytosorbentsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.005/15/2025HYPRHyperfineB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$1.20 ➝ $1.005/14/2025HYPRHyperfineWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$1.29 ➝ $0.685/2/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/3/2025CTSOCytosorbentsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.004/1/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/24/2025HYPRHyperfineLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$1.503/20/2025HYPRHyperfineB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$1.50 ➝ $1.203/18/2025HYPRHyperfineWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$1.10 ➝ $1.292/25/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPYXApyx Medical$47.29M1.23N/AN/A$0.78 per share1.97CTSOCytosorbents$35.33M1.50N/AN/A$0.52 per share1.63HYPRHyperfine$11.73M3.61N/AN/A$1.17 per share0.47VAPOVapotherm$68.67M0.20N/AN/A($9.01) per share-0.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPYXApyx Medical-$18.71M-$0.55N/AN/AN/A-58.59%-137.98%-36.74%8/6/2025 (Estimated)CTSOCytosorbents-$28.51M-$0.28N/AN/AN/A-49.47%-118.54%-42.31%8/12/2025 (Estimated)HYPRHyperfine-$44.24M-$0.54N/AN/AN/A-309.42%-57.54%-50.38%N/AVAPOVapotherm-$58.19M-$8.51N/A∞N/A-76.74%N/A-68.08%N/ALatest VAPO, APYX, CTSO, and HYPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025CTSOCytosorbents-$0.08-$0.06+$0.02-$0.02$9.01 million$8.73 million5/13/2025Q1 2025HYPRHyperfine-$0.12-$0.12N/A-$0.12$2.82 million$2.14 million5/8/2025Q1 2025APYXApyx Medical-$0.13-$0.10+$0.03-$0.10$9.39 million$9.43 million3/31/2025Q4 2024CTSOCytosorbents-$0.07-$0.03+$0.04-$0.14$10.09 million$9.20 million3/17/2025Q4 2024HYPRHyperfine-$0.16-$0.14+$0.02-$0.14$2.30 million$2.32 million3/13/2025Q4 2024APYXApyx Medical-$0.13-$0.12+$0.01-$0.12$13.39 million$14.22 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPYXApyx MedicalN/AN/AN/AN/AN/ACTSOCytosorbentsN/AN/AN/AN/AN/AHYPRHyperfineN/AN/AN/AN/AN/AVAPOVapothermN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPYXApyx Medical3.035.464.52CTSOCytosorbents1.061.971.58HYPRHyperfineN/A6.445.73VAPOVapothermN/A0.250.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPYXApyx Medical55.33%CTSOCytosorbents32.87%HYPRHyperfine15.03%VAPOVapotherm43.08%Insider OwnershipCompanyInsider OwnershipAPYXApyx Medical16.80%CTSOCytosorbents7.30%HYPRHyperfine30.98%VAPOVapotherm15.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPYXApyx Medical27037.79 million31.32 millionOptionableCTSOCytosorbents22062.61 million51.07 millionOptionableHYPRHyperfine19077.83 million51.49 millionOptionableVAPOVapotherm2906.26 million5.27 millionNo DataVAPO, APYX, CTSO, and HYPR HeadlinesRecent News About These CompaniesNew Study Confirms Vapotherm's Unicorn™ Cannula Provides Comparable Efficacy at Lower Flow RatesMay 20, 2025 | finance.yahoo.comGlobal High-Flow Oxygen Therapy Devices Market Set to Reach USD 1,567.2 Million by 2033 Amid Rising Demand for Respiratory Care Solutions | FMIOctober 25, 2024 | fmiblog.comGlobal Active Humidifier Devices Market Projects Modest Decline Amid Shifting Respiratory Care Landscape | FMIOctober 25, 2024 | fmiblog.comDecline Looms Over Global High Flow Nasal Cannula Market to reach USD 1,063.0 Million by 2034: A Call for Innovation and Adaptation | FMIOctober 21, 2024 | fmiblog.comGlobal Endobronchial Valves Market Expected to Experience Strong Growth by 2031 | Exactitude ConsultancySeptember 24, 2024 | finance.yahoo.comVapotherm, Inc.: Vapotherm Announces Closing of MergerSeptember 20, 2024 | finanznachrichten.deVapotherm Announces Closing of MergerSeptember 20, 2024 | prnewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VAPO, SGE, RPHM, SQSP on Behalf of ShareholdersAugust 30, 2024 | stockhouse.comVAPO Stock Earnings: Vapotherm Reported Results for Q2 2024August 13, 2024 | msn.comVapotherm Reports Second Quarter 2024 Financial ResultsAugust 12, 2024 | prnewswire.comPLPL Plandaí Biotechnology, Inc.July 28, 2024 | seekingalpha.comVA20.SG,0P0001F4D7,0 (VA20.SG)July 23, 2024 | finance.yahoo.comSHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Vapotherm, Inc. - VAPOJuly 9, 2024 | prnewswire.comSHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Vapotherm, Inc. – VAPOJuly 8, 2024 | globenewswire.comThe Schall Law Firm Is Performing A Scrutiny Into Vapotherm Inc And Welcomes Investors Of VAPO To EngageJuly 1, 2024 | accesswire.comThe Schall Law Firm Is Carrying Out An Inquiry Into Vapotherm Inc And Requests Investors Of VAPO To Be Part Of ItJune 30, 2024 | accesswire.comThe Schall Law Firm Is Undertaking An Investigation Into Vapotherm Inc And Invites Investors Of VAPO To JoinJune 29, 2024 | accesswire.comThe Schall Law Firm Is Leading An Investigation Into Vapotherm Inc And Invites Investors Of VAPO To JoinJune 28, 2024 | accesswire.comThe Schall Law Firm Is Conducting A Probe Into Vapotherm Inc And Encourages VAPO Investors To ParticipateJune 27, 2024 | accesswire.comThe Schall Law Firm Is Conducting A Probe Into Vapotherm Inc And Encourages Investors Of VAPO To ParticipateJune 26, 2024 | accesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVAPO, APYX, CTSO, and HYPR Company DescriptionsApyx Medical NASDAQ:APYX$1.54 -0.12 (-7.23%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.52 -0.02 (-1.36%) As of 05/23/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. The company's Helium Plasma Technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures various hand pieces for open and laparoscopic procedures; and OEM generators, as well as related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.Cytosorbents NASDAQ:CTSO$0.84 0.00 (-0.47%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.86 +0.01 (+1.30%) As of 05/23/2025 04:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.Hyperfine NASDAQ:HYPR$0.54 -0.03 (-5.73%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.55 +0.00 (+0.22%) As of 05/23/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.Vapotherm NYSE:VAPOVapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers High Velocity Therapy systems, such as HVT 2.0, Precision Flow Hi-VNI, Precision Flow Plus, and Precision Flow Classic which delivers non-invasive ventilatory support to patients by providing heated, humidified, and oxygenated air at a high velocity to treat patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor that provides compressed air necessary to run the precision flow systems in areas of the hospital without access to a wall gas source; aerosol aeroneb adaptor to facilitate delivery of aerosolized solutions; aerosol disposable patient circuit that is designed to streamline the provision of continuous and intermittent delivery of aerosol solutions for patients; and tracheostomy adaptors that simplifies the connection of the High Velocity Therapy systems to a tracheostomy collar used to wean patients off mechanical ventilation. In addition, the company offers ProSoft cannula to provide gentle contact with the skin; and disposable products comprising single-use disposables and nasal interfaces, as well as Oxygen Assist Module, which helps clinicians maintain oxygen levels within a target range. Vapotherm, Inc. was founded in 1993 and is headquartered in Exeter, New Hampshire. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
